- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Prebiopsy 3-T Multiparametric MRI Misses Some Prostate Cancers
Missed cancers include some that are clinically significant.
Prebiopsy 3-T multiparametric MRI with cancer-negative findings missed approximately 12.6 percent of cases of prostate cancer (PCa), according to a study published in the American Journal of Roentgenology.
Researchers from South Korea sought to determine the rates and characteristics of missed cancers at prebiopsy multiparametric MRI with cancer-negative findings according to the Prostate Imaging Reporting and Data System (PI-RADS) version 2 in men with suspected prostate cancer.
A total of 584 men with suspected PCa who underwent prebiopsy 3-T multipara-metric MRI followed by subsequent biopsies participated in the study; 392 were biopsy naïve and 192 had undergone repeated biopsy. Cancer-positive findings were confirmed at systemic biopsies and cognitive MRI-targeted biopsies; cancer-negative findings were confirmed at systemic biopsies performed during subsequent follow-up. Missing and detection rates of all PCa and clinically significant cancer according to five biopsy-based definitions were determined. The likelihood of PCa at multiparametric MRI was evaluated according to PI-RADS version 2, and the results were compared.
The result showed pathologically confirmed cancers in 25 percent of patients overall. Cancer-positive MRI findings were seen in 99 men (17 percent) and, of these, 85.9 percent had PCa. Of 485 men with cancer-negative MRI findings, a total of 61 (12.6 percent) had PCa, including 46 men in the biopsy-naive group and 15 men in the repeated-biopsy group. For clinically significant cancers, the rate of missed cancers at MRI was 0.1 to 6 percent, and the detection rate was 21.2 to 83.5 percent. For detecting PCa, multiparametric MRI had 96.8 percent specificity, 87.2 percent accuracy, and 87.4 percent negative predictive value.
The researchers concluded that prebiopsy 3-T multiparametric MRI with cancer-negative findings missed approximately 12.6 percent of cases of PCa.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
The Reading Room Podcast: Emerging Trends in the Radiology Workforce
February 11th 2022Richard Duszak, MD, and Mina Makary, MD, discuss a number of issues, ranging from demographic trends and NPRPs to physician burnout and medical student recruitment, that figure to impact the radiology workforce now and in the near future.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
